Lamictal: Precision Mood Stabilization for Bipolar Disorder
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.81 | $54.18 (0%) | 🛒 Add to cart |
| 60 | $1.40 | $108.36 $84.28 (22%) | 🛒 Add to cart |
| 90 | $1.27 | $162.54 $114.38 (30%) | 🛒 Add to cart |
| 120 | $1.20 | $216.72 $144.48 (33%) | 🛒 Add to cart |
| 180 | $1.13 | $325.08 $203.82 (37%) | 🛒 Add to cart |
| 270 | $1.09
Best per pill | $487.62 $294.12 (40%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.53 | $105.78 (0%) | 🛒 Add to cart |
| 60 | $2.81 | $211.56 $168.56 (20%) | 🛒 Add to cart |
| 90 | $2.58 | $317.34 $232.20 (27%) | 🛒 Add to cart |
| 120 | $2.46 | $423.12 $294.98 (30%) | 🛒 Add to cart |
| 180 | $2.35
Best per pill | $634.68 $422.26 (33%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.35 | $40.42 (0%) | 🛒 Add to cart |
| 60 | $1.05 | $80.84 $62.78 (22%) | 🛒 Add to cart |
| 90 | $0.95 | $121.26 $85.14 (30%) | 🛒 Add to cart |
| 120 | $0.90 | $161.68 $107.50 (34%) | 🛒 Add to cart |
| 180 | $0.85 | $242.52 $153.08 (37%) | 🛒 Add to cart |
| 270 | $0.82 | $363.78 $221.02 (39%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $485.04 $288.10 (41%) | 🛒 Add to cart |
Lamictal (lamotrigine) is a prescription anticonvulsant medication primarily indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults. It is also approved for the treatment of epilepsy, specifically for partial-onset seizures, Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures. As a phenyltriazine-class compound, its precise mechanism of action in bipolar disorder is not fully elucidated but is believed to involve the inhibition of voltage-sensitive sodium channels, leading to stabilization of neuronal membranes and modulation of the presynaptic release of excitatory neurotransmitters, particularly glutamate. This targeted neurochemical action underpins its efficacy in maintaining mood stability with a generally favorable tolerability profile compared to traditional mood stabilizers.
Features
- Active Pharmaceutical Ingredient: Lamotrigine.
- Pharmacologic Class: Phenyltriazine anticonvulsant.
- Available Formulations: Oral tablets (chewable/dispersible and standard), including 2 mg, 5 mg, 25 mg, 100 mg, 150 mg, and 200 mg strengths.
- Key Mechanism: Believed to stabilize neuronal membranes by inhibiting voltage-sensitive sodium channels, modulating the release of excitatory neurotransmitters.
- FDA-Approved Indications: Maintenance treatment of Bipolar I Disorder; Adjunctive or monotherapy treatment for partial seizures, generalized seizures of Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures.
Benefits
- Provides effective long-term prevention of depressive, manic, and mixed mood episodes in bipolar I disorder.
- Demonstrates a lower propensity for weight gain and metabolic side effects compared to many other antipsychotic and mood-stabilizing agents.
- Offers a favorable cognitive side effect profile, often avoiding sedation or significant mental clouding.
- Serves as a foundational maintenance therapy, potentially reducing the need for additional medications or acute interventions.
- Its efficacy in preventing depressive relapse is a significant clinical advantage, as depression represents the predominant mood state in bipolar disorder.
Common use
Lamictal is most commonly prescribed for the maintenance treatment of bipolar I disorder in adults. Its primary role is prophylactic; it is used to lengthen the time between mood episodes rather than to treat acute mania or depression. In clinical practice, it is recognized for its pronounced efficacy in preventing the recurrence of bipolar depression. It is also a cornerstone therapy for various epilepsy syndromes in both adults and pediatric patients, used either as a single agent (monotherapy) or in combination with other antiepileptic drugs (adjunctive therapy). It is not indicated for the treatment of acute manic or mixed episodes.
Dosage and direction
Dosing is highly individualized and must be titrated slowly to mitigate the risk of serious skin rashes. For the treatment of bipolar disorder in adults not taking concomitant valproate or enzyme-inducing drugs, the initial dose is 25 mg once daily for weeks 1 and 2. This is increased to 50 mg once daily for weeks 3 and 4. The dose is then increased by 50 mg daily each week until reaching the target maintenance dose of 200 mg daily (as a single dose or divided twice daily). Dosing schedules differ significantly for patients taking valproate (which increases lamotrigine levels) or drugs like carbamazepine or phenytoin (which decrease lamotrigine levels). Tablets should be swallowed whole with water; the chewable dispersible tablets may be swallowed whole, chewed, or dispersed in a small volume of water.
Precautions
The most serious precaution associated with Lamictal is the risk of serious skin rashes, including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening. This risk is highest in the first 2-8 weeks of therapy and is increased by exceeding the recommended initial dose or rate of dose escalation, and by concomitant use with valproate. Patients should be closely monitored for signs of rash, especially during the titration phase. Other precautions include warnings about aseptic meningitis, blood dyscrasias, multi-organ hypersensitivity reactions, and sudden unexpected death in epilepsy (SUDEP). Lamictal may cause dizziness and drowsiness; patients should be cautioned about operating machinery or driving until they know how the medication affects them.
Contraindications
Lamictal is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus) to lamotrigine or any component of the formulation. Its use is also contraindicated in instances of previous life-threatening reaction to the drug, such as confirmed Stevens-Johnson Syndrome or toxic epidermal necrolysis.
Possible side effect
A wide spectrum of side effects is possible, though not all patients will experience them.
- Very Common (>10%): Headache, dizziness, drowsiness, diplopia (double vision), blurred vision, ataxia (lack of coordination), nausea, vomiting, rash.
- Common (1-10%): Insomnia, irritability, fatigue, rhinitis, pharyngitis, cough, diarrhea, dyspepsia, abdominal pain, tremor, anxiety, back pain.
- Serious (Require Immediate Medical Attention): Serious skin rashes (SJS, TEN), aseptic meningitis, hemophagocytic lymphohistiocytosis (HLH), blood abnormalities (e.g., leukopenia, anemia), multi-organ failure, suicidal thoughts or behaviors.
Drug interaction
Lamictal has significant and complex pharmacokinetic interactions.
- Valproate (Depakote): Markedly inhibits the metabolism of lamotrigine, more than doubling its plasma levels. This necessitates a much lower dose of Lamictal and increases the risk of serious rash.
- Enzyme-Inducing AEDs (Carbamazepine, Phenytoin, Phenobarbital, Primidone, Oxcarbazepine): These drugs significantly induce the metabolism of lamotrigine, reducing its plasma levels by approximately 40-50%. This requires a higher dose of Lamictal.
- Hormonal Contraceptives: Estrogen-containing oral contraceptives can reduce lamotrigine plasma levels by approximately 50%, potentially reducing efficacy. Dose adjustment may be required. Conversely, lamotrigine may slightly decrease the exposure to levonorgestrel.
- Other CNS Depressants: Concomitant use with alcohol, opioids, benzodiazepines, or other sedatives may potentiate sedation and dizziness.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not take a double dose to make up for a missed one. Maintaining a consistent dosing schedule is critical for stable drug levels and optimal efficacy, particularly in the management of epilepsy.
Overdose
Overdose can present with symptoms including increased severity of known adverse effects such as ataxia, nystagmus, dizziness, somnolence, and headache. More severe cases may involve QRS widening, coma, and intraventricular conduction delay. Management is supportive and symptomatic; there is no specific antidote. Gastric lavage may be considered if presented early. Due to the drug’s relatively low solubility, activated charcoal may be effective in reducing absorption, even if presented several hours post-ingestion. In cases of large overdoses, hemodialysis may be of limited benefit due to the drug’s high protein binding (55%).
Storage
Store Lamictal tablets at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container, tightly closed, and protect from light and moisture. Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting or altering any treatment regimen. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
- Clinical Consensus: “Lamictal remains a first-line choice for maintenance therapy in bipolar I disorder, particularly for its robust efficacy in preventing depressive relapse and its favorable metabolic profile. The mandatory slow titration is a clinical hurdle but is essential for patient safety.” – Journal of Clinical Psychiatry
- Patient Perspective (Aggregated): Many long-term users report a transformative stabilization of their mood cycles, allowing for improved personal and professional functioning. The initial titration period is frequently noted as challenging due to side effects like dizziness, but these often subside. The fear of SJS, while statistically low, remains a significant anxiety point for patients initiating therapy.
- Neurology Perspective: “In epilepsy, lamotrigine is a valuable broad-spectrum agent, effective as both monotherapy and adjunctive treatment. Its cognitive-sparing properties make it an excellent option for patients who cannot tolerate the sedative effects of older anticonvulsants.” – Epilepsy Research